Evaluation of liver function test abnormalities in patients having COVID-19 according to severity of disease
DOI:
https://doi.org/10.18203/2320-6012.ijrms20221970Keywords:
SARS-CoV-2, COVID-19, Alanine aminotransferase, Liver function tests, Alkaline phosphatase, Reverse-transcriptase polymerase chain reactionAbstract
Background: COVID-19 infection affects all major organs of body in addition to lungs. Damage done to liver varies from being hepatocellular, obstructive or mix pattern. The aim of the study was to evaluate abnormalities of LFTs, in COVID-19 patients according to disease severity in our population.
Methods: A cross sectional study, conducted at GTTH and Surgimed Hospital Lahore, on 100 patients who presented with COVID-19 in between October 2020 and September 2021. According to Symptoms, patients were marked as having mild, moderate or severe disease. Bilirubin, Albumin, ALP, ALT, AST, GGT, LDH and prothrombin time were checked at admission and subsequently. Data was analyzed using SPSS v23. Laboratory values were computed in each severity category and SD values, odds ratio, 95% confidence intervals were studied in logistic regression models. P value<0.05 were considered statistically significant.
Results: Among studied patients, 66% were male, 34% were female, mean age of 44.68±9.36 and range of 29-68 years. 29% were with mild disease, 40% with moderate disease, and 21% with severe disease level. 80% cases with rural background had moderate/severe disease levels while only 14.3% cases with severe levels were from urban areas. Only direct bilirubin showed a statistical significance with p value<0.05 in all severity groups. Other LFT’s didn’t show any significance between different severity groups.
Conclusions: Among Liver function markers only bilirubin was related to COVID-19 disease and proportional to severity of disease.
References
Dong Y, Liang X, Yu X. Prognostic value of the dynamic changes in extra vascular lung water index and angiopoietin-2 in severe multiple trauma patients with acute respiratory distress syndrome. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019;31:571-6.
Niu P, Shen J, Zhu N, Lu R, Tan W. Two-tube multiplex real-time reverse transcription PCR to detect six human coronaviruses. Virologica Sinica. 2016;31:85-8.
Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/survey---weekly-epidemiological-update. Accessed on 29 June 2022.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020.
Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, et al. SARS-asso- ciated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004;39:302-10.
Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bio- Rxiv; 2020.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med; 2020.
Hayat A, Jaffar SR, Majeed N, Abbas S, Asghar J, Tayyab N, et al. Association of liver function derangements with disease severity in Covid 19 patients. Pak Armed Forces Med J. 2020;70(1):S80-4.
National Action Plan for Corona virus disease (COVID-19) Pakistan. In: Ministry of National Health Services. Available at: https://www.nih. Accessed on
Perlman S. Another decade, another coronavirus. N Engl J Med. 2020;382:760-2.
Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20.
Cai X, Ren M, Chen F, Li L, Lei H, Wang XJBT. Blood transfusion during the COVID-19 outbreak. Blood Transfus. 2020;18(2):79-82.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-47.
Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection - a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727-32.
Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020;8(1):18.
Pititto BD, Ferreira SR. Diabetes and COVID-19: more than the sum of two morbidities. Rev Saude Pub. 2020;54(1):54-60.
Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impair- ment in COVID-19 patients: A retrospective analysis of 115 cases from a single center in Wuhan city, China. Liver Int; 2020.
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bio Med J. 2020;368(1):1-2.
Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. Characteristics of Liver Tests in COVID-19 Patients. J Hepatology; 2020.
Hao SR, Zhang SY, Lian JS, Xi Jin, Ye CY, Cai H, et al. Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study. Am J Gastroenterol. 2020;115:1075-83.
